|
Volumn 19, Issue 56, 2000, Pages 6584-6593
|
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
a b |
Author keywords
Cancer therapy; Farnesyltransferase; FTI; Geranylgeranyltransferase I; GGTI; Hypothesis driven clinical trials; Ras
|
Indexed keywords
1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID;
ANTINEOPLASTIC AGENT;
B 966;
BENZODIAZEPINE;
BMS 184878;
BMS 193269;
BZA 2B;
GERANYLGERANYLTRANSFERASE INHIBITOR;
L 745631;
LONAFARNIB;
N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE;
N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER;
N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE;
N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER;
N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE;
N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
TIPIFARNIB;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
CANCER;
CLINICAL TRIAL;
DRUG DESIGN;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG TOLERABILITY;
ENZYME INHIBITION;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
ALKYL AND ARYL TRANSFERASES;
ANIMALS;
ANTICARCINOGENIC AGENTS;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
CELL DIVISION;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
HUMANS;
MICE;
PROTO-ONCOGENE PROTEINS P21(RAS);
RHOB GTP-BINDING PROTEIN;
SUBSTRATE SPECIFICITY;
STAPHYLOCOCCUS PHAGE 3A;
|
EID: 0034722890
PISSN: 09509232
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.onc.1204146 Document Type: Review |
Times cited : (277)
|
References (74)
|